BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Federal Circuit ruling weakens drugmakers' life cycle strategy
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Federal Circuit ruling weakens drugmakers' life cycle strategy
April 15, 2014
By
Mari Serebrov
No Comments
In striking down Roche AG's method of osteoporosis treatment claims for once-monthly Boniva, the Federal Circuit may have raised the bar for using a life cycle approach to protect blockbuster drugs from generic and biosimilar competition.
BioWorld